KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Adaptive Biotechnologies (ADPT) over the last 6 years, with Q3 2025 value amounting to $163.2 million.

  • Adaptive Biotechnologies' Shares Outstanding (Diluted Average) rose 1060.61% to $163.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.2 million, marking a year-over-year increase of 1060.61%. This contributed to the annual value of $147.1 million for FY2024, which is 188.27% up from last year.
  • Adaptive Biotechnologies' Shares Outstanding (Diluted Average) amounted to $163.2 million in Q3 2025, which was up 1060.61% from $152.1 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Shares Outstanding (Diluted Average) high stood at $163.2 million for Q3 2025, and its period low was $140.4 million during Q4 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $145.6 million, with a median of $144.4 million in 2023.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first surged by 124.27% in 2023, then skyrocketed by 1060.61% in 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Shares Outstanding (Diluted Average) (Quarter) stood at $140.4 million in 2021, then rose by 1.54% to $142.5 million in 2022, then grew by 1.31% to $144.4 million in 2023, then increased by 1.88% to $147.1 million in 2024, then rose by 10.92% to $163.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $163.2 million in Q3 2025, compared to $152.1 million in Q2 2025 and $149.2 million in Q1 2025.